Brandywine Global Investment Management LLC Sells 149,402 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Brandywine Global Investment Management LLC lessened its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 59.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 100,971 shares of the specialty pharmaceutical company's stock after selling 149,402 shares during the period. Brandywine Global Investment Management LLC owned approximately 0.31% of Collegium Pharmaceutical worth $2,893,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. New Age Alpha Advisors LLC bought a new position in Collegium Pharmaceutical during the 4th quarter valued at about $40,000. TD Private Client Wealth LLC boosted its stake in Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock valued at $66,000 after acquiring an additional 483 shares during the last quarter. KBC Group NV grew its stake in shares of Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after purchasing an additional 982 shares during the period. Nisa Investment Advisors LLC grew its position in shares of Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after buying an additional 316 shares during the period. Finally, Virtus Fund Advisers LLC acquired a new position in Collegium Pharmaceutical during the third quarter valued at approximately $72,000.

Remove Ads

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL traded down $0.76 during trading on Monday, reaching $27.38. 484,864 shares of the stock were exchanged, compared to its average volume of 438,259. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The stock has a 50-day moving average price of $29.88 and a 200-day moving average price of $32.03. Collegium Pharmaceutical, Inc. has a 12 month low of $26.64 and a 12 month high of $42.29. The firm has a market cap of $879.77 million, a PE ratio of 11.80 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares in the company, valued at $4,330,048.32. The trade was a 20.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Colleen Tupper sold 10,445 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the transaction, the chief financial officer now owns 165,246 shares of the company's stock, valued at approximately $4,959,032.46. This represents a 5.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 109,193 shares of company stock valued at $3,243,594 over the last quarter. 3.98% of the stock is owned by company insiders.

Analyst Ratings Changes

COLL has been the subject of a number of research reports. Piper Sandler lowered their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research note on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective on the stock in a research note on Friday, January 10th. Finally, HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.